These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31471409)

  • 21. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
    Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
    Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
    [No Abstract]   [Full Text] [Related]  

  • 28. Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up.
    Ćojbašić I; Mačukanović-Golubović L; Vučić M; Ćojbašić Ž
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e526-e531. PubMed ID: 31239209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia].
    Slezáková K; Mistrík M; Bátorová A
    Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G; Hamid M; Jalaeikhoo H
    Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
    Lee SE; Choi SY; Song HY; Kim SH; Choi MY; Park JS; Kim HJ; Kim SH; Zang DY; Oh S; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Lee WS; Chang MH; Park J; Kwon JH; Kim DW
    Haematologica; 2016 Jun; 101(6):717-23. PubMed ID: 26888022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
    Etienne G; Guilhot J; Rea D; Rigal-Huguet F; Nicolini F; Charbonnier A; Guerci-Bresler A; Legros L; Varet B; Gardembas M; Dubruille V; Tulliez M; Noel MP; Ianotto JC; Villemagne B; Carré M; Guilhot F; Rousselot P; Mahon FX
    J Clin Oncol; 2017 Jan; 35(3):298-305. PubMed ID: 28095277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy.
    Burwick RM; Kuo K; Brewer D; Druker BJ
    Obstet Gynecol; 2017 May; 129(5):831-834. PubMed ID: 28383372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Imatinib in Paediatric CML - A Single Centre Study.
    Smeding C; Szydło A; Pieluszczak K; Grzeszkiewicz K; Pawelec K
    In Vivo; 2019; 33(3):869-875. PubMed ID: 31028210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
    Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
    Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.
    Chandran RK; Geetha N; Sakthivel KM; Kumar RS; Krishna KMNJ; Sreedharan H
    Blood Cells Mol Dis; 2019 Jul; 77():51-60. PubMed ID: 30959263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.